Recently Featured

FDA Collaborates to Enhance Rare Disease Product Development

February 27, 2026
The FDA is actively engaging with a wide array of stakeholders, including patients, caregivers, and pharmaceutical manufacturers, to bolster the development of products targeting rare diseases. This collaborative approach aims to streamline the regulatory process, ensuring that innovative therapies reach the market more efficiently. In recent years, the increasing focus on rare diseases has highlighted…

MoonLake Confirms Positive Phase 2 Results Ahead of FDA Submission for Arthritis Drug

February 27, 2026
MoonLake Immunotherapeutics has reported promising Phase 2 data for its investigational drug, demonstrating a clinically meaningful benefit in patients suffering from an aggressive form of inflammatory arthritis. This announcement, made to Endpoints News, positions the company favorably as it prepares for an upcoming submission to the FDA. The data not only underscores the drug’s potential…

FDA Reversal Boosts Moderna, But Not Other Vaccine Companies

February 27, 2026
The FDA’s recent decision to review Moderna’s mRNA-1010, a seasonal flu vaccine, has sparked a notable surge in the company’s stock, reflecting a recovery that has been building over recent months. However, this positive momentum has not extended to other vaccine manufacturers, highlighting a distinct divergence in market reactions. During a “Type A” meeting, the…

Internal Disorder in Lipid Nanoparticles May Improve Cargo Delivery in Cells

February 26, 2026
Lipid nanoparticles may deliver better when they are a little disorganized. That’s according to new research from a study led by scientists at the University of Copenhagen that will be presented at the Biophysical Society Annual Meeting in San Francisco from February 21-25. Their research focused on lipid nanoparticles (LNPs), which were crucial to the…

Ongoing Cases